Contineum Therapeutics, Inc Class A Common Stock
Yahoo Finance • 2 days ago
Bristol Myers Stock Tumbles on ‘Confounding’ Trial Results
Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a major patent cliff in 2028. Continue Reading... Full story
Yahoo Finance • 20 days ago
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
Contineum Therapeutics, Inc. (NASDAQ:CTNM) has received the result biotech investors never want to see: one of its partnered drugs missed the primary endpoint of a Phase 2 trial. JNJ-5120/PIPE-307, which Contineum developed and Johnson & J... Full story
- JNJ
Mentioned:
Yahoo Finance • last month
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know about: It's a healthcare investor. Jo... Full story
Yahoo Finance • 2 months ago
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
SAN DIEGO, July 30, 2026--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic... Full story
- JNJ
Mentioned:
Yahoo Finance • 8 months ago
Cheap high flyer healthcare stocks - high momentum and low valuation
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As earnings season ramps up and geopolitical tensions keep affecting the markets, below is a list of the top 10 heal... Full story
Yahoo Finance • last year
Contineum Therapeutics Reports Positive Topline Data From PIPE-791 Phase 1b PET Trial
(RTTNews) - Contineum Therapeutics, Inc. (CTNM) on Thursday announced positive topline data from its PIPE-791 Phase 1b positron emission tomography (PET) trial, which met its primary endpoint. The Phase 1b study was designed to assess the... Full story
Yahoo Finance • last year
Contineum Therapeutics Non-GAAP EPS of -$0.62
* Contineum Therapeutics press release [https://seekingalpha.com/pr/20190078-contineum-therapeutics-reports-second-quarter-2025-financial-results-updates-key-clinical] (NASDAQ:CTNM [https://seekingalpha.com/symbol/CTNM]): Q2 Non-GAAP EPS... Full story
Yahoo Finance • last year
Contineum completes enrollment in Phase 1b PET trial cohorts
SAN DIEGO - Contineum Therapeutics (NASDAQ:CTNM), a clinical-stage biotech currently trading at $4.53 and according to InvestingPro analysis showing signs of being overvalued, has completed enrollment of healthy volunteer and progressive m... Full story
Yahoo Finance • last year
ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair
PRINCETON, N.J.--(BUSINESS WIRE)--ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug di... Full story
- ARTV